Reforgene named among China's Top 100 Innovative Pharmaceutical Companies 2026
Recently, the 2026 China Pharmaceutical Innovation 100 conference hosted by E Pharmacy Manager concluded successfully. The conference officially released the authoritative list of "2026 China Top 100 Innovative Pharmaceutical Enterprises", and Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") was successfully listed, joining the ranks of China's Top 100 innovative pharmaceutical enterprises for 2026.
This edition of the 2026 China Pharmaceutical Innovation 100 conference brought together leading figures from government, industry, academia, research, investment and clinical fields, focusing on frontier hotspots such as CGT cell and gene therapy, nucleic acid medicines, clinical development of new drugs and the globalization of biomedicine, to jointly discuss the path of high-quality development of China's innovative drug industry. Relying on professional big data and a quantitative evaluation system, the list is a core wind vane for judging the innovation hard power of domestic biomedical enterprises.
As a leading innovative gene editing drug company in China, Reforgene takes gene editing technology as its core and is dedicated to bringing novel medicines to life. Relying on continuously increasing R&D investment and a leading gene editing drug platform, it has accumulated pioneering achievements in multiple drug directions including hematology, cardiovascular, metabolic and infectious diseases. In hematology, Reforgene has completed the confirmatory clinical trial of its beta-thalassemia product RM001, with all subjects maintaining transfusion independence and excellent clinical data achieved. Its alpha-thalassemia product RM004 has conducted the world's first human trial for this disease and successfully cured the first patient. Reforgene's ophthalmology product for Usher syndrome has obtained clinical approval in both China and the United States, the world's first medicine of its kind for this indication. At present, Reforgene's gene editing therapies for chronic diseases are accelerating into the clinical stage.
This selection is high recognition by the industry of Reforgene's comprehensive strength in technological innovation, drug R&D and industrialization potential. Thanks to the long-term accumulation of underlying gene editing technology and R&D platforms, Reforgene is entering a new development stage of scaled pipeline advancement and global value realization.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.